(Q43907665)

27 November 2017

title

In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells (English)

1 reference

27 November 2017

1 reference

1

1 reference

27 November 2017

Tian Z

2

1 reference

27 November 2017

Andronicos NM

series ordinal

3

1 reference

27 November 2017

Rizvi S

series ordinal

4

1 reference

27 November 2017

Allen BJ

series ordinal

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Breast Cancer Research and Treatment

27 November 2017

published in

1 reference

27 November 2017

volume

71

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

149-159

1 reference

Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

The urokinase-type plasminogen activator system in cancer metastasis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Radioimmunotherapy with alpha-emitting nuclides

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Plasminogen activation in human leukemia and in normal hematopoietic cells.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

The human ENO1 gene product (recombinant human α-enolase) displays characteristics required for a plasminogen binding protein

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013850107791

7 January 2021

Identifiers

DOI

10.1023/A:1013850107791

1 reference

Dimensions Publication ID

27 November 2017

1024002035

0 references

1 reference